Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. (DXCM) is widely described in its own communications as a global leader in glucose biosensing and real-time continuous glucose monitoring (CGM) for people with diabetes. The Dexcom news stream features regular updates on product launches, clinical evidence, coverage decisions, financial performance, and leadership developments, all centered on its CGM and biosensing technology.
Investors and healthcare observers following DXCM news will find detailed announcements on new products such as the Dexcom G7 15 Day CGM System, which is designed to provide real-time glucose readings over extended wear, and Dexcom Smart Basal, a CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes using long-acting insulin. News items also cover enhancements to the Stelo app for metabolic health, AI-enabled features like meal logging, and integrations with connected devices and insulin delivery systems.
Dexcom’s news releases highlight clinical and real-world data presented at major conferences, including the European Association for the Study of Diabetes (EASD), where the company shares findings on outcomes such as pregnancy complications, diabetic ketoacidosis management, and cost-effectiveness of CGM compared to fingersticks. Coverage and reimbursement milestones, such as expanded access under the Régie de l’assurance maladie du Québec (RAMQ) and other public programs, are also frequent topics.
Financial results and guidance updates, leadership transitions, and board appointments are reported through earnings releases and Form 8-K related press announcements. For anyone tracking how CGM technology, biosensing, and digital health tools are evolving in diabetes and metabolic health, the Dexcom news page offers an ongoing record of the company’s product, clinical, and corporate developments. Bookmark this page to follow the latest DXCM press releases and regulatory disclosures as they are issued.
Dexcom (NASDAQ: DXCM) unveiled 16 global diabetes advocates for its World Diabetes Day campaign on November 14, 2025.
The advocates — selected from ~1,000 open-call submissions — span ages 6 to 68, represent Type 1, Type 2 and prediabetes, and come from four continents and five countries. The campaign highlights personal stories and use of Dexcom glucose biosensing technology via editorial portraits and a Los Angeles photoshoot that included visits from Lance Bass and Retta.
More details and individual stories are available at Dexcom.com/WorldDiabetesDay.
Dexcom (NASDAQ: DXCM) announced that as of November 7, 2025 Québec will expand RAMQ coverage to include Dexcom Continuous Glucose Monitoring (CGM) for eligible adults (age 18+) living with type 2 diabetes who are treated with intensive insulin therapy (IIT).
Eligibility requires IIT (at least three injections/day or insulin pump) plus one or more clinical criteria such as unmet HbA1C targets, frequent hypoglycemia, or impaired hypoglycemia awareness. The release highlights Dexcom G7 features including a 30-minute warm-up, predictive Urgent Low Soon alert (3.1 mmol/L within 20 minutes), waterproof rating (submerged up to eight feet for 24 hours), and Apple Watch connectivity.
Dexcom (Nasdaq: DXCM) reported third quarter 2025 results on October 30, 2025 with revenue up 22% YoY to $1.209 billion (20% organic). The company raised full‑year 2025 revenue guidance to $4.630–$4.650 billion (≈15% growth) and updated margin targets: non‑GAAP gross margin ~61%, non‑GAAP operating margin ~20–21%, and adjusted EBITDA margin ~29–30%. GAAP operating income rose to $242.5 million (20.1% of revenue), up 480 bps year‑over‑year. Strategic items included an AI meal‑logging feature, expanded G7 access in Ontario, submission of Dexcom Smart Basal to FDA, and Stelo surpassing $100 million revenue in its first year. Cash, cash equivalents and marketable securities totaled $3.32 billion.
Dexcom (NASDAQ:DXCM) announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025.
Dr. Ashley serves as Chair of the Department of Medicine at Stanford, overseeing 15 divisions and over 800 faculty. His work spans precision medicine, data science, AI, and digital health. He has co-founded seven biotechnology companies and co-directs Stanford’s biomedical innovation-translation program, Catalyst.
Dexcom said Dr. Ashley will provide a clinical perspective for strategic guidance on medical technology development and healthcare innovation. Quotes from Eric Topol and President/interim CEO Jake Leach highlight his fit with Dexcom’s growth and focus on advancing metabolic health.
Dexcom (NASDAQ:DXCM) has scheduled its third quarter 2025 earnings release and conference call for October 30, 2025. The company will release its financial results after market close, followed by a management conference call at 4:30 p.m. Eastern Time.
Investors can access the conference call via webcast through Dexcom's investor relations website at investors.dexcom.com, or by dialing (888) 414-4585 (US/Canada) or (646) 960-0331 (International) using confirmation ID "9430114".
Dexcom (NASDAQ:DXCM), a leader in glucose biosensing, will present significant innovations and clinical evidence at the 61st EASD Conference. The company will introduce Dexcom Smart Basal, a new integrated titration module currently under FDA and CE mark review, designed to simplify basal insulin management.
Key clinical findings include: reduced neonatal complications in gestational diabetes using CGM versus fingersticks, optimized glucose control through exercise timing in pregnant Type 1 diabetes patients, and a 65% reduction in hypoglycemic events when switching from fingersticks to Dexcom CGM. New cost-effectiveness data from Japan demonstrates CGM's superiority over fingersticks for Type 2 diabetes patients on insulin therapy.
Dexcom (NASDAQ:DXCM), the global leader in glucose biosensing, has launched its first open call for diabetes advocates in the U.S. and Canada. The initiative invites individuals aged 2 and older living with all types of diabetes and prediabetes to apply through September 19, 2025, for a chance to be featured in Dexcom's 2025 World Diabetes Day campaign.
Selected candidates will participate in a Los Angeles photoshoot and receive ongoing support from Dexcom throughout the year to attend events and connect with the diabetes community. The campaign is supported by Nick Jonas, multi-platinum recording artist and diabetes advocate. Applications can be submitted at Dexcom.com/WorldDiabetesDay until September 19 at 12 p.m. PDT.
Dexcom (NASDAQ:DXCM), a leading medical device company, has announced its participation in two upcoming investor conferences. The company's management will present at the 2025 Wells Fargo Healthcare Conference on September 3, 2025, at 2:15 PM EDT, and at the Baird 2025 Global Healthcare Conference on September 10, 2025, at 2:00 PM EDT.
Investors can access the webcasts through Dexcom's investor relations website at investors.dexcom.com, where recordings will also be archived for future viewing.
Synchron, a brain-computer interface (BCI) company, has strengthened its executive team with two significant appointments. Andy Rasdal, former DexCom (NASDAQ: DXCM) CEO, joins as Chief of Staff while continuing his Board position, and Mark Brister takes the role of VP R&D.
Rasdal brings over 30 years of medical device industry experience, notably leading DexCom through FDA approval and IPO, and previously serving as President of Medtronic Vascular. Brister contributes 38 years of experience in medical device technologies, with over 450 patents and involvement in launching more than 100 products.
These appointments aim to advance Synchron's Stentrode® BCI through U.S. clinical trials and prepare for global market entry, potentially transforming treatment for millions with motor impairment.
Dexcom (NASDAQ:DXCM) reported strong Q2 2025 financial results with revenue growing 15% year-over-year to $1.157 billion. The company achieved GAAP operating income of $212.6 million, representing 18.4% of revenue. Dexcom also announced a CEO succession plan, with Jake Leach set to become CEO effective January 1, 2026, while current CEO Kevin Sayer will transition to executive chairman.
Key highlights include FDA clearance for the Dexcom G7 15 Day CGM System, launch of AI-based Smart Food Logging, and enhanced Stelo customer experience. The company raised its 2025 revenue guidance to $4.600-$4.625 billion (14-15% growth) while maintaining guidance for other metrics, including Non-GAAP Operating Margin of approximately 21%.
The company maintains a strong financial position with $2.93 billion in cash, cash equivalents, and marketable securities.